A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Launched by CYTOS BIOTECHNOLOGY AG · Dec 14, 2007
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Mild to moderate perennial allergic rhinoconjunctivits due to hypersensitization towards house dust mite allergens
- Exclusion Criteria:
- • Clinically relevant other allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments
- • Use of any concomitant medication that could affect the patient's study treatment response or assessment results
About Cytos Biotechnology Ag
Cytos Biotechnology AG is a biopharmaceutical company focused on the development of innovative therapeutic solutions for unmet medical needs. With a strong emphasis on harnessing the power of the immune system, Cytos is dedicated to advancing its proprietary technologies in the fields of vaccine development, immunotherapy, and targeted biologics. The company’s robust pipeline reflects its commitment to scientific excellence and patient-centric approaches, positioning it as a key player in the biotechnology landscape. Through strategic collaborations and a focus on clinical research, Cytos aims to bring transformative treatments to market, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Schlieren, , Switzerland
Patients applied
Trial Officials
Philipp Mueller, MD
Study Director
Cytos Biotechnology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials